营养不良型大疱性表皮松解症（Dystrophic Epidermolysis Bullosa，DEB）是一种罕见的遗传性皮肤疾病，由COL7A1基因突变引起，COL7A1基因编码VII型胶原蛋白（C7 ...

ZEVASKYN, the first and only cell-based gene therapy for patients with recessive dystrophic epidermolysis bullosa (RDEB), now commercially available in the U.S. - - Ann & Robert H. Lurie Children ...

The therapy, known as Vyjuvek and made by Krystal Biotech, will soon be available for patients with dystrophic epidermolysis bullosa, a genetic disease that causes painful blisters and persistent ...

Dystrophic epidermolysis bullosa is a rare genetic blistering skin disease caused by mutations in COL7A1, which encodes type VII collagen (C7). Beremagene geperpavec (B-VEC) is a topical ...

Abeona Therapeutics has received FDA approval for ZEVASKYN, the first autologous cell-based gene therapy for treating wounds in patients with recessive dystrophic epidermolysis bullosa (RDEB), a ...

as the first and only autologous cell-based gene therapy for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB), a serious and ...

The study, published in Lancet Neurology, detailed the "head-to-head" trial implemented by the researchers to test two drugs, mexiletine and lamotrigine, on people with the condition. The trial ...

Researchers from Royal Children's Hospital, the University of Melbourne and affiliated organizations published data from a study that aimed to investigate the potential of benfotiamine, which is a ...

Zevaskyn is supplied as a single-dose of up to 12 cellular sheets consisting of a patient's own viable, gene-modified cells that contain functional copies of the COL7A1 gene, which express ...

Krystal Biotech, Inc. announced that the European Commission has approved VYJUVEK® (beremagene geperpavec-svdt) for the treatment of wounds in patients with dystrophic epidermolysis bullosa (DEB ...